Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

NCT03313206 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Mucosal Melanomas

Interventions

DRUG: Pembrolizumab
PROCEDURE: Surgery
RADIATION: IMRT
DRUG: Lenvatinib

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris